Cardiac biomarkers in HIV-exposed uninfected children

AIDS

Volumn 27, Issue 7, 2013, Pages 1099-1108

  Wilkinson, James D ^a   Williams, Paige L ^b   Leister, Erin ^b   Zeldow, Bret ^b   Shearer, William T ^c   Colan, Steven D ^d   Siberry, George K ^e   Dooley, Laurie B ^f   Scott, Gwendolyn B ^a   Rich, Kenneth C ^g   Lipshultz, Steven E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antiretroviral drugs; Cardiac biomarkers; Echocardiography; HIV; Pediatric

Indexed keywords

ABACAVIR; ALCOHOL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TROPONIN T; ZIDOVUDINE;

ARTICLE; CD4+ T LYMPHOCYTE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EXPOSURE; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CONTRACTILITY; HIV EXPOSED UNINFECTED CHILDREN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATERNAL CARE; MEAN END SYSTOLIC SEPTAL THICKNESS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DETERMINATION; SCORING SYSTEM; SYSTOLE; TOBACCO; VIRUS LOAD;

ALCOHOL DRINKING; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHILD OF IMPAIRED PARENTS; CHILD, PRESCHOOL; DIDEOXYNUCLEOSIDES; ECHOCARDIOGRAPHY; FEMALE; HIV SEROPOSITIVITY; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MOTHERS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS; SMOKING; TROPONIN T; UNITED STATES; VENTRICULAR FUNCTION, LEFT; VIRAL LOAD;

EID: 84879111349     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835cf21c     Document Type: Article

References (57)

1. Whitmore SK, Zhang X, Taylor AW, Blair JM. Estimated number of infants born to HIV-infected women in the United States and five dependent areas. J Acquir Immune Defic Syndr 2011; 57:218-222.
2. Department of Health and Human Services Centers for Disease Control and Disease Prevention. HIV Surveillance Supplemental Report: Table 4 [serial online]. 2011. Available at: http://www.cdc.gov/hiv/surveillance/resources/ reports/2010supp-vol16no2/pdf/table4-5.pdf [Accessed 17 February 2012].
3. Lipshultz SE, Shearer WT, Thompson B, Rich KC, Cheng I, Orav EJ, et al. Cardiac effects of antiretroviral therapy in HIVnegative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study). J Am Coll Cardiol 2011; 57:76-85.
4. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med 2010; 61:169-185.
5. Lipshultz SE, Fisher SD, Lai WW, Miller TL. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 2003; 17 (Suppl 1):S96-S122.
6. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30:1042-1049.
7. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96:2641-2648.
8. Lipshultz SE, Somers MJ, Lipsitz SR, Colan SD, Jabs K, Rifai N. Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. Pediatrics 2003; 112:79-86.
9. Lipshultz SE, Wong JC, Lipsitz SR, Simbre VC 2nd, Zareba KM, Galpechian V, et al. Frequency of clinically unsuspected myocardial injury at a children's hospital. Am Heart J 2006; 151:916-922.
10. Lipshultz SE, Simbre VC 2nd, Hart S, Rifai N, Lipsitz SR, Reubens L, et al. Frequency of elevations in markers of cardiomyocyte damage in otherwise healthy newborns. Am J Cardiol 2008; 102:761-766.
11. Soongswang J, Durongpisitkul K, Nana A, Laohaprasittiporn D, Kangkagate C, Punlee K, et al. Cardiac troponin T: a marker in the diagnosis of acute myocarditis in children. Pediatr Cardiol 2005; 26:45-49.
12. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351:145-153.
13. Ratnasamy C, Kinnamon DD, Lipshultz SE, Rusconi P. Associations between neurohormonal and inflammatory activation and heart failure in children. Am Heart J 2008; 155:527-533.
14. Rusconi PG, Ludwig DA, Ratnasamy C, Mas R, Harmon WG, Colan SD, et al. Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure. Am Heart J 2010; 160:776-783.
15. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108:2317-2322.
16. Kaneko K, Kanda T, Hasegawa A, Suzuki T, Kobayashi I, Nagai R. C-reactive protein as a prognostic marker in lymphocytic myocarditis. Jpn Heart J 2000; 41:41-47.
17. Pye M, Rae AP, Cobbe SM. Study of serum C-reactive protein concentration in cardiac failure. Br Heart J 1990; 63:228-230.
18. Williams PL, Seage GR III, Van Dyke RB, Siberry GK, Griner R, Tassiopoulos K, et al. for the Pediatric HIV/AIDS Cohort Study. A trigger-based design for evaluating the safety of antiretroviral exposure in uninfected children of HIV-infected mothers. Am J Epidemiol 2012; 175:950-961.
19. Wilkinson JD, Lee DJ, Arheart KL. Secondhand smoke exposure and C-reactive protein levels in youth. Nicotine Tob Res 2007; 9:305-307.
20. Quest Diagnostics. Congestive Heart Failure (CHF) Risk Testing [serial online]. 2011. Available at: http://www.questdiagnostics.com/hcp/topics/bnp/bnp. html [Accessed 13 July 2011].
21. Agarwal SK, Avery CL, Ballantyne CM, Catellier D, Nambi V, Saunders J, et al. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. Clin Chem 2011; 57:891-897.
22. Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998; 44:1358-1361.
23. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 2003; 49:1258-1271.
24. Nowatzke WL, Cole TG. Stability of N-terminal pro-brain natriuretic peptide after storage frozen for one year and after multiple freeze-thaw cycles. Clin Chem 2003; 49:1560-1562.
25. Cauliez B, Guignery J, Marinier S, Mariau I, Lavoinne A. Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system. Ann Clin Biochem 2008; 45:318-319.
26. Sluysmans T, Colan SD. Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol 2005; 99:445-457.
27. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al., D:A:D. Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426.
28. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of myocardial infarction with ABC use: an FCA meta-analysis. Abstract presented at: 18th Conference on Retroviruses and Opportunistic Infections (CROI); February 28, 2011; Boston, MA.
29. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database (RAMQ). J Acquir Immune Defic Syndr 2011; 57:245-253.
30. Sax P. Abacavir and cardiovascular risk: still no clarity. Journal Watch HIV/AIDS Clinical Care [serial online]. Available at: http://aids-clinical-care. jwatch.org/cgi/content/full/2011/627/1 [Accessed 27 June 2011].
31. Krasemann T. QT prolongation in the newborn and maternal alcoholism. Cardiol Young 2004; 14:565-566.
32. Krasemann T, Klingebiel S. Influence of chronic intrauterine exposure to alcohol on structurally normal hearts. Cardiol Young 2007; 17:185-188.
33. Löser H, Pfefferkorn JR, Themann H. Alcohol in pregnancy and fetal heart damage. Klin Padiatr 1992; 204:335-339.
34. Adickes ED, Mollner TJ, Makoid MC. Teratogenic effects of ethanol during hyperplastic growth in cardiac myocyte cultures. Alcohol Clin Exp Res 1993; 17:988-992.
35. Wold LE, Norby FL, Hintz KK, Colligan PB, Epstein PN, Ren J. Prenatal ethanol exposure alters ventricular myocyte contractile function in the offspring of rats: influence of maternal Mg2R supplementation. Cardiovasc Toxicol 2001; 1:215-224.
36. Mone SM, Gillman MW, Miller TL, Herman EH, Lipshultz SE. Effects of environmental exposures on the cardiovascular system: prenatal period through adolescence. Pediatrics 2004; 113:1058-1069.
37. Wilkinson J, Cheng I, Thompson B, Rifai N, Shearer WT, Rich KC, et al. Are cardiac biomarkers useful in assessing cardiac structure and function in children exposed to the human immunodeficiency virus in utero? Pediatr Res 2009; E-PAS2009:4341.212. Abstract presented at: Pediatric Academic Societies (PAS); May 4, 2009; Baltimore, MD. http://www.abstracts2view.com/pasall/view.php?nu= PAS09L1-2079.
38. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23:2629-2636.
39. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324:808-815.
40. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332:1738-1743.
41. Newby LK, Rodriguez I, Finkle J, Becker RC, Hicks KA, Hausner E, et al. Troponin measures during drug development-considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. Am Heart J 2011; 162:64-73.
42. Herman EH, Lipshultz SE, Rifai N, Zhang J, Papoian T, Yu Z-X, et al. Cardiac troponin T: elevated serum levels and loss from cardiac myocytes in doxorubicin toxicity. Cancer Res 1998; 58:195-197.
43. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda, et al. Correlation between serum levels of cardiac troponin-T and the severity of chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17:2237-2243.
44. Herman EH, Zhang J, Rifai N, Lipshultz SE, Hasinoff BB, Chadwick DP, et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 2001; 48:297-304.
45. Herman E, Zhang J, Knapton A, Lipshultz SE, Rifai N, Sistare F. Serum cardiac troponin T as a biomarker for acute myocardial injury induced by low doses of isoproterenol in rats. Cardiovasc Toxicol 2006; 6:211-221.
46. Zhang J, Knapton A, Lipshultz SE, Weaver JL, Herman EH. Isoproterenol-induced cardiotoxicity in Sprague-Dawley rats: correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury. Toxicol Pathol 2008; 36:277-278.
47. Thompson KL, Rosenzweig BA, Zhang J, Knapton AD, Honchel R, Lipshultz SE, et al. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol 2010; 66:303-314.
48. Berridge BR, Pettit S, Walker DB, Jaffe AS, Schultze AE, Herman E, et al. A transformational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. Am Heart J 2009; 158:21-29.
49. Lipshultz SE. Ventricular dysfunction clinical researchininfants, children and adolescents. Prog Ped Cardiol 2000; 12:1-28.
50. Herman E, Knapton AD, Rosen E, Zhang J, Estis J, Agee SJ, et al. Baseline serum cardiac troponin I concentrations in Sprague-Dawley, spontaneous hypertensive, Wistar, Wistar-Kyoto, and Fisher rats as determined with an ultrasensitive immunoassay. Toxicol Pathol 2011; 39:653-663.
51. Dunn ME, Coluccio D, Hirkaler G, Mikaelian I, Nicklaus R, Lipshultz SE, et al. The complete pharmacokinetic profile of serum cardiac troponin I in the rat and the dog. Toxicol Sci 2011; 123:368-373.
52. Cooper LT Jr. Myocarditis. N Engl J Med 2009; 360:1526-1538.
53. Schultheiss HP, Kuhl U. Viral myocarditis: diagnosis, aetiology and management. Drugs 2009; 69:1287-1302.
54. Cocker M, Friedrich MG. Cardiovascular magnetic resonance of myocarditis. Curr Cardiol Rep 2010; 12:82-89.
55. Lim P, Monin JL, Monchi M, Garot J, Pasquet A, Hittinger L, et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 2004; 25:2048-2053.
56. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-1614.
57. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M, et al. Cost-effectiveness analysis of HLA BM5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14:335-342. Development